Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10641797 | 0.98 | LPL (0.49) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL20906870 | 0.98 | LPL (0.49) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL7351056 | 0.95 | HDAC4 (0.47) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL10388289 | 0.88 | GRIN2D (0.47) | HDAC4MEF2D | |
| SCHEMBL5253062 | 0.84 | LPL (0.50) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL1188674 | 0.81 | RAPGEF4 (0.49) | HDAC4MEF2D | |
| SCHEMBL23845445 | 0.80 | NPC1 (0.44) | HDAC4MEF2D | |
| SCHEMBL2089168 | 0.80 | THRA (0.54) | S1PR1S1PR4S1PR3SPHK1 | |
| SCHEMBL11871771 | 0.80 | LPL (0.56) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL29767685 | 0.80 | LPL (0.56) | LPLLIPGS1PR1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | LPL 4818/4885LIPG 4880/4885S1PR1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.